Latest News
China Medical University Hospital achieves triple HIMSS validations

Source: HealthcareIT News, By Adam Ang

China Medical University Hospital in Taichung, Taiwan has been recently validated for three HIMSS Digital Maturity Models: Stage 7 for the Infrastructure Adoption Model (INFRAM), revalidation of Stage 7 for the Electronic Medical Record Adoption Model (EMRAM), and Stage 6 for the Adoption Model for Analytics Maturity (AMAM). 

The INFRAM measures an organisation's maturity in infrastructure and associated technology capabilities. The EMRAM measures their clinical outcomes, patient engagement, and clinician use of EMR technology, while the AMAM gauges their analytics capabilities.

CMUH is the first hospital in Taiwan to be validated for Stage 7 INFRAM. It was able to achieve this feat in just four months after achieving Stage 6. It attributed its achievement to its infrastructure strategy which took inspiration from the Chinese Zodiac. 

The hospital is also the first in the country to be validated for Stage 6 AMAM. It was able to demonstrate some mature applications of analytics, including the analysis of medication expenses that helped it realise an annual cost savings of approximately NT$ 200 million ($6.2 million). Another example is its ARDiTeX (ARDS Technology System) visualisation panel that is used in the Respiratory ICU. It enabled the reduction in 28-day mortality among diagnosed patients with ARDS (Acute Respiratory Distress Syndrome).

Additionally, CMUH was revalidated for Stage 7 of the EMRAM. To meet the requirements of this stage, the hospital introduced major changes in its EMR system. These include the implementation of the Electronic Medication Administration Record, integration of records across multidisciplinary teams, and establishing interoperability with the Med-cloud database of Taiwan's National Health Insurance. 

HIMSS also recognised its antimicrobial AI platform, the Intelligent Anti-Microbial System (i.A.M.S.), as a noteworthy use of the EMR. It is a four-in-one AI-driven platform that identifies drug-resistant strains and predicts and monitors the risk of infectious sepsis and mortality. It also makes smart drug dosage recommendations and automatic comparisons of drug-drug interactions and allergy history. In just three months after its implementation in June 2021, i.A.M.S. helped cut the mortality rate due to sepsis by 7.1%, compared to 13.4% in the same period in the previous year.

To date, CMUH has developed 16 AI-driven services and 50 dashboards based on the Microsoft Power Business Intelligence platform, which are all implemented broadly across clinical and operational areas. 

For full release please visit HealthcareIT News:

Information appearing on this website (images and texts, unless otherwise indicated) is the property of IBMI. To use or share, please indicate the source.
©Institute for Biotechnology and Medicine Industry (IBMI) All rights reserved.
Address:16F.-1, No.3, Park St., Nangang Dist., Taipei City 115, Taiwan (R.O.C.) Contact Number:(02)2655-8168 Fax:(02)2655-7978